Therapeutic potential of the stromal vascular fraction in COVID-19
- Authors: Pavlov V.N.1, Kazikhinurov A.A.1, Kazikhinurov R.A.1, Agaverdiyev M.A.1, Gareev I.F.1, Beylerli O.A.1, Mazorov B.Z.1
-
Affiliations:
- Bashkir State Medical University
- Issue: Vol 13, No 1 (2021)
- Pages: 15-26
- Section: Reviews
- URL: https://journals.rcsi.science/vszgmu/article/view/64213
- DOI: https://doi.org/10.17816/mechnikov64213
- ID: 64213
Cite item
Abstract
The new coronavirus infection (COVID-19) is already known to cause serious respiratory illnesses such as pneumonia and lung failure. COVID-19 has caused catastrophic damage to the public health, economic and social stability. As COVID-19 has resulted in enormous human toll and serious economic loss that poses a global threat, urgent understanding of the current situation and the development of strategies to mitigate the spread of the virus is required. Today, many studies are being carried out around the world to study the pathogenesis of COVID-19, where the development of a “cytokine storm” or pulmonary fibrosis is a serious complication that can lead to unfavorable outcomes. This leads to the fact that a deeper understanding of the nature of the virus will allow to develop new approaches in pathogenetic therapy. In this regard, the stromal vascular fraction has tremendous therapeutic potential in COVID-19. Stromal vascular fraction provides anti-inflammatory and immunomodulatory effects and promotes the restoration and regeneration of damaged tissues. The availability, the ability to obtain a significant volume of viable cells of the stromal vascular fraction population, such as adipose tissue stem / stromal cells, as well as their use by the intravenous route, has proven safe and effective in other forms of lung disease, including fibrotic diseases. In other words, the goal of this therapy for COVID-19 is to eliminate the inflammatory process, restore trophic and regenerate damaged tissues, and remodel fibrous and connective tissue. However, stromal vascular fraction is not currently approved for the prevention or treatment of COVID-19 cases. However, clinical trials are ongoing to ensure maximum understanding in terms of efficacy and safety. In this paper, we will discuss this new approach to the use of stromal vascular fraction therapy, which serves as a “ray of hope” in the fight against severe forms of COVID-19
Full Text
##article.viewOnOriginalSite##About the authors
Valentin N. Pavlov
Bashkir State Medical University
Email: pavlovvn.journal@mail.ru
ORCID iD: 0000-0003-2125-4897
SPIN-code: 2799-6268
MD, Dr. Sci. (Med.), Professor, Corresponding Member of the RAS
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanAlbert A. Kazikhinurov
Bashkir State Medical University
Email: alberturo@mail.ru
ORCID iD: 0000-0001-9284-7855
SPIN-code: 1841-6587
MD, Dr. Sci. (Med.), Professor
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanRustem A. Kazikhinurov
Bashkir State Medical University
Email: Royuro@mail.ru
ORCID iD: 0000-0001-6813-8549
SPIN-code: 1196-4134
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanMurad A. Agaverdiyev
Bashkir State Medical University
Email: isimbasium@bk.ru
ORCID iD: 0000-0002-7991-0319
SPIN-code: 5954-3750
MD, PhD student
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanIlgiz F. Gareev
Bashkir State Medical University
Author for correspondence.
Email: ilgiz_gareev@mail.ru
ORCID iD: 0000-0002-4965-0835
SPIN-code: 3839-0621
PhD, Senior Research Associate
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanOzal A. Beylerli
Bashkir State Medical University
Email: obeylerli@mail.ru
ORCID iD: 0000-0002-6149-5460
SPIN-code: 7392-3152
Research Associate
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of BashkortostanBakhodur Z. Mazorov
Bashkir State Medical University
Email: mazorov94@bk.ru
ORCID iD: 0000-0002-6873-0291
SPIN-code: 1764-1691
Russian Federation, 3 Lenin Str., Ufa, 450008, Republic of Bashkortostan
References
- Shi H, Yang G, Gao C, et al. Management of neurosurgical patients during the COVID-19 pandemic. Creative Surgery and Oncology. 2020;10(3):177–182. (In Russ.) doi: 10.24060/2076-30932020-10-3-177-182
- Izmailov A, Beylerli O, Pavlov V, et al. Management strategy for cancer patients in the context of the COVID-19 epidemic. Semin Oncol. 2020;47(5):312–314. doi: 10.1053/j.seminoncol.2020.07.004
- Pavlov V, Beylerli O, Gareev I, Solis LFT. COVID-19-related intracerebral hemorrhage. Front Aging Neurosci. 2020;12:600172. doi: 10.3389/fnagi.2020.600172
- Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi: 10.1016/j.arr.2020.101205
- Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi: 10.1136/postgradmedj-2020-138234
- Baptista LS. Adipose stromal/stem cells in regenerative medicine: Potentials and limitations. World J Stem Cells. 2020;12(1):1–7. doi: 10.4252/wjsc.v12.i1.1
- Daher SR, Johnstone BH, Phinney DG, March KL. Adipose stromal/stem cells: basic and translational advances: the IFATS collection. Stem Cells. 2008;26(10):2664–2665. doi: 10.1634/stemcells.2008-0927
- Sheykhhasan M, Wong JKL, Seifalian AM. Human adipose-derived stem cells with great therapeutic potential. Curr Stem Cell Res Ther. 2019;14(7):532–548. doi: 10.2174/1574888X14666190411121528
- Si Z, Wang X, Sun C, et al. Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies. Biomed Pharmacother. 2019;114:108765. doi: 10.1016/j.biopha.2019.108765
- Al-Ghadban S, Bunnell BA. Adipose tissue-derived stem cells: Immunomodulatory effects and therapeutic potential. Physiology (Bethesda). 2020;35(2):125–133. doi: 10.1152/physiol.00021.2019
- Li J, Curley JL, Floyd ZE, et al. Isolation of human adipose-derived stem cells from lipoaspirates. Methods Mol Biol. 2018;1773:155–165. doi: 10.1007/978-1-4939-7799-4_13
- Baer PC. Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo and in vitro. World J Stem Cells. 2014;6(3):256–265. doi: 10.4252/wjsc.v6.i3.256
- Van Dongen JA, Harmsen MC, Stevens HP. Isolation of stromal vascular fraction by fractionation of adipose tissue. Methods Mol Biol. 2019;1993:91–103. doi: 10.1007/978-1-4939-9473-1_8
- Li Z, Mu D, Liu C, et al. The cell yields and biological characteristics of stromal/stem cells from lipoaspirate with different digestion loading ratio. Cytotechnology. 2020;72(2):203–215. doi: 10.1007/s10616-020-00369-9
- Nürnberger S, Lindner C, Maier J, et al. Adipose-tissue-derived therapeutic cells in their natural environment as an autologous cell therapy strategy: the microtissue-stromal vascular fraction. Eur Cell Mater. 2019;37:113–133. doi: 10.22203/eCM.v037a08
- Zanata F, Shaik S, Devireddy RV, et al. Cryopreserved adipose tissue-derived stromal/stem cells: Potential for applications in clinic and therapy. Adv Exp Med Biol. 2016;951:137–146. doi: 10.1007/978-3-319-45457-3_11
- Davis TA, Anam K, Lazdun Y, et al. Adipose-derived stromal cells promote allograft tolerance induction. Stem Cells Transl Med. 2014;3(12):1444–1450. doi: 10.5966/sctm.2014-0131
- Peñuelas O, Melo E, Sánchez C, et al. Antioxidant effect of human adult adipose-derived stromal stem cells in alveolar epithelial cells undergoing stretch. Respir Physiol Neurobiol. 2013;188(1):1–8. doi: 10.1016/j.resp.2013.04.007
- Solodeev I, Orgil M, Bordeynik-Cohen M, et al. Cryopreservation of stromal vascular fraction cells reduces their counts but not their stem cell potency. Plast Reconstr Surg Glob Open. 2019;7(7):e2321. doi: 10.1097/GOX.0000000000002321
- Li X, Zeng X, Xu Y, et al. Mechanisms and rejuvenation strategies for aged hematopoietic stem cells. J Hematol Oncol. 2020;13(1):31. doi: 10.1186/s13045-020-00864-8
- Bora P, Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation. Stem Cell Res Ther. 2017;8(1):145. doi: 10.1186/s13287-017-0598-y
- Bowles AC, Wise RM, Gerstein BY, et al. Adipose stromal vascular fraction attenuates T(H)1 cell-mediated pathology in a model of multiple sclerosis. J Neuroinflammation. 2018;15(1):77. doi: 10.1186/s12974-018-1099-3
- Ahmed TA, Shousha WG, Abdo SM, et al. Human adipose-derived pericytes: biological characterization and reprogramming into induced pluripotent stem cells. Cell Physiol Biochem. 2020;54(2):271–286. doi: 10.33594/000000219
- Ramakrishnan VM, Boyd NL. The adipose stromal vascular fraction as a complex cellular source for tissue engineering applications. Tissue Eng Part B Rev. 2018;24(4):289–299. doi: 10.1089/ten.TEB.2017.0061
- Nyberg E, Farris A, O’Sullivan A, et al. Comparison of stromal vascular fraction and passaged adipose-derived stromal/stem cells as point-of-care Agents for bone regeneration. Tissue Eng Part A. 2019;25(21–22):1459–1469. doi: 10.1089/ten.TEA.2018.0341
- Pavón A, Beloqui I, Salcedo JM, Martin AG. Cryobanking mesenchymal stem cells. Methods Mol Biol. 2017;1590:191–196. doi: 10.1007/978-1-4939-6921-0_14
- Aronowitz JA, Lockhart RA, Hakakian CS. A Method for isolation of stromal vascular fraction cells in a clinically relevant time frame. Methods Mol Biol. 2018;1773:11–19. doi: 10.1007/978-1-4939-7799-4_2
- Wong DE, Banyard DA, Santos PJF, et al. Adipose-derived stem cell extracellular vesicles: A systematic review. J Plast Reconstr Aesthet Surg. 2019;72(7):1207–1218. doi: 10.1016/j.bjps.2019.03.008
- Sun Y, Chen S, Zhang X, Pei M. Significance of cellular cross-talk in stromal vascular fraction of adipose tissue in neovascularization. Arterioscler Thromb Vasc Biol. 2019;39(6):1034–1044. doi: 10.1161/ATVBAHA.119.312425
- Zhang Y, Cai J, Zhou T, et al. Improved long-term volume retention of stromal vascular fraction gel grafting with enhanced angiogenesis and adipogenesis. Plast Reconstr Surg. 2018;141(5):676e–686e. doi: 10.1097/PRS.0000000000004312
- Semon JA, Zhang X, Pandey AC, et al. Administration of murine stromal vascular fraction ameliorates chronic experimental autoimmune encephalomyelitis. Stem Cells Transl Med. 2013;2(10):789–796. doi: 10.5966/sctm.2013-0032
- Premaratne GU, Ma LP, Fujita M, et al. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J Cardiothorac Surg. 2011;6:43. doi: 10.1186/1749-8090-6-43
- Blaber SP, Webster RA, Hill CJ, et al. Analysis of in vitro secretion profiles from adipose-derived cell populations. J Transl Med. 2012;10:172. doi: 10.1186/1479-5876-10-172
- Jayaramayya K, Mahalaxmi I, Subramaniam MD, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep. 2020;53(8):400–412. doi: 10.5483/BMBRep.2020.53.8.121
- Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in COVID-19? Obesity (Silver Spring). 2020;28(7):1191–1194. doi: 10.1002/oby.22843
- Yu S, Cheng Y, Zhang L, et al. Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats. Stem Cell Res Ther. 2019;10(1):333. doi: 10.1186/s13287-019-1474-8
- Jiang M, Bi X, Duan X, et al. Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model. Exp Ther Med. 2020;19(3):1725–1732. doi: 10.3892/etm.2020.8430
- Engela AU, Hoogduijn MJ, Boer K, et al. Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol. 2013;173(2):343–354. doi: 10.1111/cei.12120
- Hajmousa G, Harmsen MC. Assessment of energy metabolic changes in adipose tissue-derived stem cells. Methods Mol Biol. 2017;1553:55–65. doi: 10.1007/978-1-4939-6756-8_5
- Fukui E, Funaki S, Kimura K, et al. Adipose tissue-derived stem cells have the ability to differentiate into alveolar epithelial cells and ameliorate lung injury caused by elastase-induced emphysema in mice. Stem Cells Int. 2019;2019:5179172. doi: 10.1155/2019/5179172
- Cho HH, Kim YJ, Kim JT, et al. The role of chemokines in proangiogenic action induced by human adipose tissue-derived mesenchymal stem cells in the murine model of hindlimb ischemia. Cell Physiol Biochem. 2009;24(5-6):511–518. doi: 10.1159/000257495
- Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 2020;11(2):462–464. doi: 10.14336/AD.2020.0301
- Gentile P, Sterodimas A. Adipose stem cells (ASCs) and stromal vascular fraction (SVF) as a potential therapy in combating (COVID-19)-disease. Aging Dis. 2020;11(3):465–469. doi: 10.14336/AD.2020.0422
- Bradley KC, Finsterbusch K, Schnepf D, et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 2019;28(1):245–256.e4. doi: 10.1016/j.celrep.2019.05.105
- Hoogduijn MJ, Lombardo E. Mesenchymal stromal cells anno 2019: Dawn of the therapeutic era? Concise review. Stem Cells Transl Med. 2019;8(11):1126–1134. doi: 10.1002/sctm.19-0073
- Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P. Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell Biol Toxicol. 2020;36(1):83–102. doi: 10.1007/s10565-019-09493-5
- Atkins JW, West K, Kasow KA. Current and future cell therapy standards and guidelines. Hematol Oncol Clin North Am. 2019;33(5):839–855. doi: 10.1016/j.hoc.2019.05.008
- Ji F, Li L, Li Z, et al. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med. 2020;9(7):813–814. doi: 10.1002/sctm.20-0083
- Rossnagl S, Ghura H, Groth C, et al. A subpopulation of stromal cells controls cancer cell homing to the bone marrow. Cancer Res. 2018;78(1):129–142. doi: 10.1158/0008-5472.CAN-16-3507
- Fang Y, Zhang Y, Zhou J, Cao K. Adipose-derived mesenchymal stem cell exosomes: a novel pathway for tissues repair. Cell Tissue Bank. 2019;20(2):153–161. doi: 10.1007/s10561-019-09761-y
- Kubrova E, D’Souza RS, Hunt CL, et al. Injectable biologics: What is the evidence? Am J Phys Med Rehabil. 2020;99(10):950–960. doi: 10.1097/PHM.0000000000001407
- Khalaj K, Figueira RL, Antounians L, et al. Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19? J Extracell Vesicles. 2020;9(1):1795365. doi: 10.1080/20013078.2020.1795365
- Putra A, Rosdiana I, Darlan DM, et al. Intravenous administration is the best route of mesenchymal stem cells migration in improving liver function enzyme of acute liver failure. Folia Med (Plovdiv). 2020;62(1):52–58. doi: 10.3897/folmed..e47712
- Martinez J, Zoretic S, Moreira A, Moreira A. Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis. Stem Cell Res Ther. 2020;11(1):272. doi: 10.1186/s13287-020-01764-x
- West WH, Beutler AI, Gordon CR. Regenerative injectable therapies: Current evidence. Curr Sports Med Rep. 2020;19(9):353–359. doi: 10.1249/JSR.0000000000000751
- Zimmerlin L, Rubin JP, Pfeifer ME, et al. Human adipose stromal vascular cell delivery in a fibrin spray. Cytotherapy. 2013;15(1):102–108. doi: 10.1016/j.jcyt.2012.10.009
- Di Liddo R, Bertalot T, Borean A, et al. Leucocyte and Platelet-rich Fibrin: a carrier of autologous multipotent cells for regenerative medicine. J Cell Mol Med. 2018;22(3):1840–1854. doi: 10.1111/jcmm.13468